Radiotherapy Combination with Immunotherapy in Metastatic Solid Tumors

Havva BEYAZa , Yılmaz TEZCANa
aAnkara Yıldırım Beyazıt University Faculty of Medicine, Ankara Bilkent City Hospital, Department of Radiation Oncology, Ankara, Türkiye

Beyaz H, Tezcan Y. Radiotherapy combination with immunotherapy in metastatic solid tumors. In: Şendur MAN, ed. Current Immunotherapy Landscape for Solid Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.136-40.

ABSTRACT
The use of immunotherapy and radiotherapy combinations in cancer treatment has been increasing in recent years. In addition to the local effects of radiotherapy on tumor cells, many preclinical and clinical studies have been conducted, considering that the expected benefit from immunotherapy will improve with the immunological response in tumor microenvironment by radiotherapy. It has been reported the combination is effective and safe. Especially in oligometastatic disease, stereotactic radiotherapy has been found to cause more effective abscobal effects than conventional doses, and the use of fractionated stereotactic radiotherapy is generally recommended. Although the timing of radiotherapy, dose/fractionation, sequencing, and the optimal interval which are the factors that will increase the effectiveness of the combination are not clearly described, general recommendations are presented in this paper.

Keywords: Radiotherapy; immunotherapy; neoplasm metastasis

Referanslar

  1. Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol. 2010;31(4):363-72. [Crossref]  [PubMed]
  2. Tepper JE, Foote RL, Michalski JM. Gunderson&Tepper's Clinical Radiation Oncology. 5th ed. Philadelphia US: Elsevier; 2021. p.438-46.
  3. Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs. 2011;71(8):1093-104. [Crossref]  [PubMed]
  4. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498-509. [Crossref]  [PubMed]
  5. Pointer KB, Pitroda SP, Weichselbaum RR. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022;8(1):9-20. [Crossref]  [PubMed]
  6. Gao Z, Zhao Q, Xu Y, Wang L. Improving the efficacy of combined radiotherapy and immunotherapy: focusing on the effects of radiosensitivity. Radiat Oncol. 2023;18(1):89. [Crossref]  [PubMed]  [PMC]
  7. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-71. [Crossref]  [PubMed]  [PMC]
  8. Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, et al. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 2015;75(11):2232-42. [Crossref]  [PubMed]  [PMC]
  9. Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, et al. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer J. 2016;22(4):257-66. [Crossref]  [PubMed]  [PMC]
  10. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234-41. [Crossref]  [PubMed]
  11. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862-70. [Crossref]  [PubMed]
  12. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-31. [Crossref]  [PubMed]  [PMC]
  13. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al.; PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-50. [Crossref]  [PubMed]
  14. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60-5. [Crossref]  [PubMed]  [PMC]
  15. Turchan WT, Chmura SJ. The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review. Ann Palliat Med. 2021;10(5):6028-44. [Crossref]  [PubMed]
  16. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. Erratum in: N Engl J Med. 2010;363(13):1290. [Crossref]  [PubMed]  [PMC]
  17. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020;38(25):2830-8. [Crossref]  [PubMed]  [PMC]
  18. Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5(9):1276-82. [Crossref]  [PubMed]  [PMC]
  19. Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020;8(2):e001001. [Crossref]  [PubMed]  [PMC]
  20. Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021;9(5):467-75. Erratum in: Lancet Respir Med. 2021;9(3):e29. [Crossref]  [PubMed]
  21. McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, et al. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2021;39(1):30-7. [Crossref]  [PubMed]  [PMC]
  22. Onderdonk BE, Luke JJ, Bhave SR, Karrison TG, Chang P, Zha Y, et al. Multi-Site SBRT and Sequential Pembrolizumab: Treated Metastasis Control and Immune-Related Expression Predict Outcomes. Int J Radiat Oncol Biol Phys. 2019;104(5):1190-1. [Crossref]
  23. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al; CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700-12. [Crossref]  [PubMed]
  24. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018;36(16):1611-8. [Crossref]  [PubMed]  [PMC]
  25. Trapani S, Manicone M, Sikokis A, D'Abbiero N, Salaroli F, Ceccon G, et al. Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review. Crit Rev Oncol Hematol. 2019;142:9-15. [Crossref]  [PubMed]
  26. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158-68. [Crossref]  [PubMed]
  27. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23-34. Erratum in: N Engl J Med. 2018;379(22):2185. [Crossref]
  28. Shibaki R, Akamatsu H, Fujimoto M, Koh Y, Yamamoto N. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy. Ann Oncol. 2017;28(6):1404-5. [Crossref]  [PubMed]
  29. Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023;24(3):e121-e32. [Crossref]  [PubMed]
  30. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1306-10. [Crossref]  [PubMed]  [PMC]
  31. Teng F, Kong L, Meng X, Yang J, Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. Cancer Lett. 2015;365(1):23-9. [Crossref]  [PubMed]
  32. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589-95. [Crossref]  [PubMed]  [PMC]
  33. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. [Crossref]  [PubMed]  [PMC]
  34. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379-88. [Crossref]  [PubMed]  [PMC]